BioMarin's Wild Ride: Analyst Downgrade vs. Promising Data

BioMarin stock dipped nearly three percent after a Neutral rating from HC Wainwright overshadowed positive drug data for VOXZOGO and PALYNZIQ. This relatively significant move for BioMarin, a stock down 16% YTD and 35% from its September high, highlights investor sensitivity despite encouraging clinical trial results and earlier gains fueled by optimism around potential Federal Reserve interest rate cuts. Long-term investors who bought in five years ago would be down 25%. The market is waiting to see if BioMarin's progress can reverse its current slump. Hosted on Acast. See acast.com/privacy for more information.